Ibrutinib based drugs: price, availability and description

Ibrutinib is an antineoplastic agent and a first-in-class Bruton's tyrosine kinase (BTK) inhibitor. This enzyme is crucial for the survival and proliferation of malignant B-cells. By blocking BTK, Ibrutinib halts the growth of cancer cells and induces cell death. It is indicated for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia.